Search

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Focus on Alliance Management

US Privacy Statement

CIA Reporting Requirements

Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US

Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Protein Degraders: Changing the Game in Cancer Drug Discovery

SPEVIGO approved for expanded indications in China and the US

FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Why role models matter for black veterinarians: One doctor's story

Cookie Statement

Fighting Rabies in Madagascar | Boehringer Ingelheim US

Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

She finds purpose in the saddle and pursues a passion for horses – at home and work

Xochimilco

With its presence in Greece of more than a half century,

Growing fresh produce for a cause at our U.S. headquarters

Social Impact | COVID-19 | Boehringer Ingelheim US

Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.

Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.

Recognized as an inclusive workplace for the fifth time

Recognized as an Inclusive Workplace for the Fifth Time

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.

Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers